Acute Kidney Injury is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys.
The Acute Kidney Injury (AKI) market report by DelveInsight provides current treatment practices, emerging drugs, Acute Kidney Injury (AKI) market share of the individual therapies, current and forecasted Acute Kidney Injury (AKI) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Acute Kidney Injury (AKI) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Acute Kidney Injury Epidemiology
- The highest incident cases of AKI were recorded in the United States in 2017 was 895,078
- Among the EU5 countries, Germany had the highest AKI diagnosed cases in 2017 was 82,902
- Acute Kidney Injury affects males and females equally
Acute Kidney Injury Market
Market Size of Acute Kidney Injury in the United States in 2017 was USD 2,907 Million
Acute Kidney Injury Market Drivers
- Robust Pipeline Activity
- Increased incidence of hospitalization
- Reimbursement policies
Acute Kidney Injury Market Barriers
- Disease burden
- Morbidity/ mortality
- Disease management & treatment
Acute Kidney Injury Emerging Therapies
(Drug: companies logos)
- EA-230: Exponential Biotherapies
- bRESCAP: Alloksys
- ANG-3777 : Angion Biomedica
- QPI-1002: Quark Pharmaceuticals
- recAP: AM Pharma
- Reltecimod: AtoxBio
- ASP1128: Astellas Pharma
- Levosimendan : Orion Pharma
- MB-102: MediBeacon
- Ruconest: Pharming Technologies
1. Key Insights
2. The Report contains
3. Acute Kidney Injury Market (AKI): Overview at a Glance
3.1. Market Share Distribution of AKI in 2017
3.2. Market Share Distribution of AKI in 2030
4. Acute Kidney Injury (AKI): Disease Background and Overview
4.1. Introduction
4.2. Symptoms
4.3. Types of Acute Kidney Injury
4.4. Stages Classification
4.5. Risk Factors
4.6. Etiology
4.7. Pathophysiology
4.8. Biomarkers
4.9. Diagnosis
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. 7MM Total Incident Patient Population of AKI
5.3. 7MM Total Discharge Diagnosed Population of AKI
6. United States
6.1. Assumptions and Rationale
6.2. Acute Kidney Injury Incident Cases in the US
6.3. Acute Kidney Injury Discharge Diagnosed Cases in the US
6.4. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in the US
6.5. Acute Kidney Injury Risk Factor Associated Cases in the US
6.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the US
7. EU5
7.1. Assumptions and Rationale
7.2. Germany
7.2.1. Acute Kidney Injury Incident Cases in Germany
7.2.2. Acute Kidney Injury Discharge Diagnosed Cases in Germany
7.2.3. Acute Kidney Injury Stage-Wise Discharged Diagnosed Cases in Germany
7.2.4. Acute Kidney Injury Risk Factor Associated Cases in Germany
7.2.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Germany
7.3. France
7.3.1. Acute Kidney Injury Incident Cases in France
7.3.2. Acute Kidney Injury Discharge Diagnosed Cases in France
7.3.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in France
7.3.4. Acute Kidney Injury Risk Factor Associated Cases in France
7.3.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in France
7.4. Italy
7.4.1. Acute Kidney Injury Incident Cases in Italy
7.4.2. Acute Kidney Injury Discharge Diagnosed Cases in Italy
7.4.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Italy
7.4.4. Acute Kidney Injury Risk Factor Associated Cases in Italy
7.4.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Italy
7.5. Spain
7.5.1. Acute Kidney Injury Incident Cases in Spain
7.5.2. Acute Kidney Injury Discharge Diagnosed Cases in Spain
7.5.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Spain
7.5.4. Acute Kidney Injury Risk Factor Associated Cases in Spain
7.5.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Spain
7.6. United Kingdom
7.6.1. Acute Kidney Injury Incident Cases in the UK
7.6.2. Acute Kidney Injury Discharge Diagnosed Incident Cases in the UK
7.6.3. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in the UK
7.6.4. Acute Kidney Injury Risk Factor Associated Cases in the UK
7.6.5. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in the UK
8. Japan
8.1.1. Assumptions and Rationale
8.1.2. Acute Kidney Injury Incident Cases in Japan
8.1.3. Acute Kidney Injury Discharge Diagnosed Cases Japan
8.1.4. Acute Kidney Injury Stage-Wise Discharge Diagnosed Cases in Japan
8.1.5. Acute Kidney Injury Risk Factor Associated Cases in Japan
8.1.6. Acute Kidney Injury Renal Transplantation Associated Delayed Graft Function Cases in Japan
9. Treatment and Prevention
10. Unmet Needs
11. Emerging Therapies
11.1. Key cross competition- Emerging Therapies
12. Emerging Therapies
12.1. EA-230: Exponential Biotherapies
12.1.1. Clinical Development
12.1.2. Clinical Trials Information
12.1.3. Safety and Efficacy
12.1.4. Product Profile
12.2. bRESCAP: Alloksys
12.2.1. Other Developmental Activities
12.2.2. Clinical Trials Information
12.2.3. Safety and Efficacy
12.2.4. Product Profile
12.3. ANG-3777 (BB3) : Angion Biomedica
12.3.1. Other Developmental Activities
12.3.2. Clinical Trials Information
12.3.3. Safety and Efficacy
12.3.4. Product Profile
12.4. QPI-1002: Quark Pharmaceuticals
12.4.1. Other Developmental Activities
12.4.2. Clinical Development
12.4.3. Clinical Trial Information
12.4.4. Safety and Efficacy
12.4.5. Advantages and Disadvantages
12.4.6. Product Profile
12.5. recAP: AM Pharma
12.5.1. Other Developmental Activities
12.5.2. Clinical Development
12.5.3. Clinical Trial Information
12.5.4. Safety and Efficacy
12.5.5. Product Profile
12.6. Reltecimod: AtoxBio
12.6.1. Other Developmental Activities
12.6.2. Clinical Development
12.6.3. Clinical Trial Information
12.6.4. Safety and Efficacy
12.6.5. Product Profile
12.7. ASP1128: Astellas Pharma
12.7.1. Other Developmental Activities
12.7.2. Clinical Development
12.7.3. Clinical Trial Information
12.7.4. Safety and Efficacy
12.7.5. Product Profile
12.8. Ruconest (Conestat alfa): Pharming Technologies
12.8.1. Other Developmental Activities
12.8.2. Clinical Development
12.8.3. Clinical Trial Information
12.8.4. Safety and Efficacy
12.8.5. Product Profile
12.9. MB-102: MediBeacon
12.9.1. Other Developmental Activities
12.9.2. Clinical Development
12.9.3. Clinical Trial Information
12.9.4. Safety and Efficacy
12.9.5. Product Profile
12.10. Levosimendan (Simdax): Orion Pharma
12.10.1. Clinical Development
12.10.2. Clinical Trial Information
12.10.3. Safety and Efficacy
12.10.4. Product Profile
13. Acute Kidney Injury: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Size of AKI in 7MM
14. United States Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of AKI
14.1.2. Market Size by Therapies
15. EU-5 Countries: Market Outlook
15.1. Germany Market Size
15.1.1. Total Market size of AKI
15.1.2. Market Size by Therapies
15.2. France Market Size
15.2.1. Total Market size of AKI
15.2.2. Market Size by Therapies
15.3. Italy Market Size
15.3.1. Total Market size of AKI
15.3.2. Market Size by Therapies
15.4. Spain Market Size
15.4.1. Total Market size of AKI
15.4.2. Market Size by Therapies
15.5. United Kingdom Market Size
15.5.1. Total Market size of AKI
15.5.2. Market Size by Therapies
16. Japan: Market Outlook
16.1. Japan Market Size
16.1.1. Total Market size of AKI
16.1.2. Market Size by Therapies
17. Trends in the Cost of Therapies in Acute Kidney Injury
18. Market Access and Reimbursement Scenario of Acute Kidney Injury
18.1. Centers of Medicare and Medicaid Services (US)
18.2. American Kidney Fund (AKF)
18.3. Reimbursement and Cost of Acute Kidney Injury in Europe
18.3.1. United Kingdom (England)
18.3.2. France
18.3.3. Germany
18.3.4. Italy
19. Market Drivers
20. Market Barriers
21. Case Reports
21.1. A simple real-time model for predicting acute kidney injury in hospitalized patients in the US: A descriptive modeling study
21.2. Acute kidney injury in the UK: a replication cohort study of the variation across three regional populations
21.3. Exercise-Induced Acute Kidney Injury in a Police Officer with Hereditary Renal Hypouricemia (Japan)
22. SWOT Analysis for Acute Kidney Injury
23. Appendix
23.1. Report Methodology
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/